Pictilisib

Manufactured by MedChemExpress

Sourced in United States

Pictilisib is a laboratory compound used in research. It functions as a selective inhibitor of the phosphoinositide 3-kinase (PI3K) enzyme. Pictilisib is commonly utilized in experimental studies to understand the role of the PI3K signaling pathway in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using pictilisib

Clofarabine and Pictilisib Treatment Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

Clofarabine (S1218) was obtained from Selleck Chemicals (Houston, TX) and Pictilisib (HY-50094) was obtained from MedChemExpress (Monmouth Junction, NJ). AKT (4691), p-AKT (4060), checkpoint kinase 2 (CHK2) (6334), p-CHK2(2197), H2AX (7631), p-H2AX (9718), poly ADP-ribose polymerase (PARP) (9542), cleaved PARP (5625), ribosomal protein S6 kinase beta-1 (RPS6KB1) (9202), p-RPS6KB1 (9205), BCL2 (15071), BCL2-associated X (BAX) (5023), p53 upregulated modulator of apoptosis (PUMA) (98672), and cleaved caspase 3 (9661) antibodies were all obtained from Cell Signal Technology (Danvers, MA). Ki67 (27309) antibody was obtained from Proteintech (Rosemont, IL). β-Actin antibody was obtained from Millipore Sigma (St. Louis, MO).

Khalafi S., Zhu S., Khurana R., Lohse I., Giordano S., Corso S., Al-Ali H., Brothers S.P., Wahlestedt C., Schürer S, & El-Rifai W. (2021). A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Translational Oncology, 15(1), 101260.

+ Open protocol

+ Expand

Mammary Epithelial Organoid Assay

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Epithelial cells were harvested from the mammary glands of 8 to 12-wk-old MIC mice and grown as organoids as described previously (28 (link)). Roughly 10,000 mammary epithelial cells were cultured in eight-well chambers in the organotypic medium consisted of Epicult-B mouse medium (Stem Cell Technologies, 05610), knockout serum replacement (Gibco, 10828010), penicillin/streptomycin, 10 ng/mL EGF, 25 μg/mL insulin (Sigma, 10156), and 1 μg/mL hydrocorticone for 6 d to allow formation of acinar structures. Subsequently, doxycycline was added to growth media either in the presence or absence of drug treatments for 8 d, with media changes every 48 h. The following inhibitors, along with their working doses, were used: GSK-126 (MedChem Express, Cat#HY-13470, 2 μM), EPZ6438 (MedChem Express, Cat#13803, 2 μM), Torin-1 (Selleckchem, Cat#S2827, 250 nM), Rapamycin (MedChem Express, Cat#HY-10219, 100 nM), IWP-2 (STEMCELL Technologies, Cat#721220, 20 nM), MS-177 (MedChem Express, Cat#HY-148333, 5 μM), A-395 (MedChem Express, Cat#HY-101512, 2.5 μM), 3-Deazaneplanocin A hydrochloride (DZNep) (MedChem Express, Cat#HY-10442, 2 μM), and Pictilisib (GDC-0941) (MedChem Express, Cat#HY-50094, 5 μM).

Liu L., Xiao B., Hirukawa A., Smith H.W., Zuo D., Sanguin-Gendreau V., McCaffrey L., Nam A.J, & Muller W.J. (2023). Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways. Proceedings of the National Academy of Sciences of the United States of America, 120(33), e2303010120.

+ Open protocol

+ Expand

Combinatorial Cancer Treatment Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

CUDC-907, rapamycin (mTOR inhibitor), and trichostatin A (HDAC inhibitor) were purchased from Selleck Chemicals (Houston, TX, USA). Pictilisib (PI3K-Akt inhibitor), carboplatin, paclitaxel, 3-methyladenine (3-MA, autophagy inhibitor), chloroquine (CQ, autophagy inhibitor), MHY1485 (mTOR activator), and SP600125 (JNK inhibitor) were purchased from MedChemExpress (Monmouth Junction, NJ, USA). N-acetyl-L-cysteine (NAC) was purchased from Sigma-Aldrich (St. Louis, MO, USA). CUDC-907 powder was dissolved at 10 M in pure dimethyl sulfoxide (DMSO) and stored at − 20 °C. Control cells were treated with DMSO as a vehicle.

Jian Z., Han Y., Zhang W., Li C., Guo W., Feng X., Li B, & Li H. (2022). Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer. Cell & Bioscience, 12, 135.

+ Open protocol

+ Expand

Evaluating Pharmacological Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

NVP-2, Nutlin-3a, 5-fluorouridine, 5-fluorodeoxyuridine, THZ531 and Pictilisib were from MedChemExpress. 5-fluorouracil, Senexin A, OTS964 and Triptolide were from Selleck Chemicals. YLK-5–124 and THAL-SNS-032 were a gift from Nathanael S. Gray’s Laboratory (Stanford University, USA). iCDK9 was a gift from Qiang Zhou’s Laboratory (University of California, Berkley, USA). PP2A activator DT-061 was a gift from Jukka Westermarck’s Laboratory (University of Turku, Finland).

Wang Z., Mačáková M., Bugai A., Kuznetsov S.G., Hassinen A., Lenasi T., Potdar S., Friedel C.C, & Barborič M. (2023). P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway. Nucleic Acids Research, 51(4), 1687-1706.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!